Mobile website
Archive > Volume 25 Issue 6 > 2018,25(6):620-628. DOI:10.3872/j.issn.1007-385X.2018.06.012 Prev Next
Clinical Research
Expression of RUNX1 isoformsand its clinical significance in acute leukemia
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
[Abstract] Objective: To investigate the relationship between the expression of RUNX1 isoforms and the clinical curative effect and the prognosis of acute leukemia (AL), in order to provide valuable experimental data for the individualized treatment, MRD (minimal residual disease) monitoring and prognosis prediction of AL. Methods: AL patients with primary treatment (PT, n=88) and recrudescence (RC, n=10) that treated at the Department of Hematology of Affiliated Hospital of Guangdong Medical University from April,2012 to April, 2013 were included in this study. Real-time PCR was used to examine the mRNA expression of RUNX1 isoforms (RUNX1a and RUNX1b / c) in PT patients, RC patients and controls (non-malignant hematological disease patients). The changes in mRNA expression of RUNX1a and RUNX1b/c in patients before and after the chemotherapy were also observed. Results：(1)The expression levels of RUNX1a mRNA in AML and ALL PT group and AML RC group was significantly higher than those of control group (P<0.05); The expression level of RUNX1a mRNA in AML PT group was increased compared with ALL PT group (P<0.05). (2) The expression levels of RUNX1a and RUNX1b/c mRNA in AML and ALL patients at initial treatment were significantly higher than those after complete remission (CR) (P<0.05). (3) By comparing the expression levels of RUNX1a and RUNX1b/c mRNA at initial diagnosis,there was no significant difference between 6-month death group and survival group, CR group and NCR (non-complete remission)group after first cycle of chemotherapy, or the high leukocyte group and non-high leukocyte group (all P>0.05).The expression level of RUNX1a mRNA in AML-ETO positive group was higher than that of negative group (P<0.05). (4) The expression levels of RUNX1a and RUNX1b/c mRNA in patients with acute leukemia decreased with the increasing chemotherapy cycle, and significantly increased when had a relapse, which may even succeed the initial level.Conclusion: RUNX1a isoforms participate in the pathogenesis of acute leukemia, and isrelated to the relapse of AML. The expression levels of RUNX1a and RUNX1b/c mRNA are related to the clinical efficacy that can be used as an indicator of curative effect, but have no significant correlation with the prognosis of the disease.Dynamic monitor of theexpression levels of RUNX1a and RUNX1b/c isomers can be used as an effective indicator of MRD monitoring after chemotherapy,which can be used to evaluate the efficacy and identify the risk of recurrence at early stage.
Keywords:
Project Supported:
Project supported by the Science and Technology Planning Project of Guangdong Province（No. 2014A020212300, 2016A020215149）, and the Zhanjiang City Financial Resources for Competitive Science and Technology Distribution Program（No. 2016A06003）
Clc Number:
